Lotus Pharmaceuticals, Inc.
Simbols: LTUS
PNK
0.00401
USDTirgus cena šodien
-651.6106
P/E koeficients
-3.8330
PEG koeficients
0.11M
MRK Cap
- 0.00%
DIV ienesīgums
Lotus Pharmaceuticals, Inc. (LTUS) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 2.7 | 2.7 | 2.9 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -32.8 | -32.8 | -32.8 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -2.7 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 30 | 32.7 | 29.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.net-debt | 0 | 0.1 | 0.1 | 0.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 0 | 0 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | 0 | 0 | 0 | 0 |
Biežāk uzdotie jautājumi
Kas ir Lotus Pharmaceuticals, Inc. (LTUS) kopējie aktīvi?
Lotus Pharmaceuticals, Inc. (LTUS) kopējie aktīvi ir 5681.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.000.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir Lotus Pharmaceuticals, Inc. (LTUS) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -18812.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 116683.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 18812.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.